MANE
VeradermicsBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
Current thesis
Positive VDPHL01 efficacy signals across male and female development programs, multiple second-half 2026 readouts, and stated runway into 2030 could support further clinical de-risking and eventual commercial optionality.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +2.1.
What can break
Clinical safety, tolerability, regulatory, enrollment, or launch execution could delay the program.
Momentum
93
Value
46
Sentiment
41
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $105.00 · Bull $145.00 · Bear $72.00
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-17
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $161.00
Why
Momentum93 · Δ7d +2.1
Value46 · Δ7d 0.0
Sentiment41 · Δ7d +13.3
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
93
26% active weight
Current posture
7d trendFlat
Δ7d
+2.1
Δ21d
+0.7
Value
46
39% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.7
Sentiment
41
34% active weight
Current posture
7d trendImproving
Δ7d
+13.3
Δ21d
+13.1
Why this grade
Composite grade B. Momentum 92.9 / Value 46.4 / Sentiment 41.4
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$4.65B
Beta
-
Shares Out
41.78M
P/E (TTM) · Derived
-49.9
P/S (TTM)
-
P/FCF (TTM)
-
Rev YoY
-
EPS YoY
+105.8%
Gross Margin
-
Op Margin
-
Net Debt
-$141.86M
Current Ratio
59.12
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology